🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

$AFMD - Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO) affimed.com/wp-content/upl…

$AFMD Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association

Wunderschöner Abschluss vom Deutsch-Amerikanischen Freundschaftsfest #Heidelberg 2023 Stadt Heidelberg Rhein-Neckar-Zeitung Heidelberg-aktuell #volksfest #heidelberg24 Süddeutsche Zeitung ntv Nachrichten Eckart Würzner

FDA Fast track designation for AFM13 in combination with AlloNK #Affimed #WhyWeFightCancer #celltherapy #CureCancer

𝗜𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀❓ Come to #BioRNConference and meet brilliant young scientists pitching their work at 1:30 pm. 🏆people the audience choose the most innovative project! 🔗lnkd.in/dQvysUw

Great start of the #BioRNConference 2023 in Heidelberg with an excellent talk by @platten_michael about „From vaccine to adoptive T cell therapy of cancer” #Celltherapy BioRN Life Science Cluster Rhine-Neckar #dkfz

Affimed announces Oral Presentation of Phase 1/2 data from AFM13 in combination with allogenic NK cells at #ASH23 Annual Meeting. #AFM $AFMD #curecancer #immunotherapy affimed.com/affimed-announ…

$AFMD “Identification of Pharmacokinetic Profile Modifiers for Bispecific Antibodies by Monitoring pH-Dependent FcRn Dissociation Using FcRn-pH-HPLC” presented by Affimed at #PEGS2023 see publication vimeo.com/857867183

$AFMD #Fightcancer #ASH23 @Affimed MD Anderson Cancer Center

$AFMD Leveraging innate cell engagers for lymphoma treatment. Interview to Affimed CMO Andreas Harstrick europeanpharmaceuticalreview.com/article/190298…

$AFMD AFM13 new study location

Excited to announce our new CEO, Dr Arndt Schottelius! An experienced biotech & pharma executive, Arndt will take Maxion to its next phase of development. Current CEO Dr John McCafferty will become CTO. #CEO #antibodies #KnotBodies #ionchannels #GPCR #drugdevelopment

Visit our booth # 16153 at #ASCO2024 to learn about our progress in developing innovative potential therapeutic options for #cancer patients. Find an overview of our presentations: investors.biontech.de/news-releases/…

🔍 Initial Ph. 2 data for GEN1046/BNT311, a next-gen bispecific #antibody candidate jointly developed with Genmab, showing 12 mo. overall survival rate of 69% when combined with pembrolizumab in PD-L1 pos. #mNSCLC patients. Learn more: investors.biontech.de/news-releases/…

Advancing our oncology strategy: by strengthening next-gen immuno-modulator capabilities, we’re enhancing one core pillar of our oncology strategy.With investigational assets like BNT327/PM8002,our pipeline aims to build a new backbone in immuno-oncology.investors.biontech.de/de/news-releas…

We are excited to be attending this year’s #SABCS24, with new interim Phase 1b/2 data for our anti-PD-L1/VEGF-A bispecific antibody candidate BNT327/PM8002 in triple-negative #BreastCancer (#TNBC). 📍Visit us at booth # 226 to explore the latest data for this asset.

$BNTX and $BMY Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types. $BNTX to receive $1.5B upfront

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars. trib.al/TKZED2e

#BioNTech schließt Milliarden-Deal mit US-Pharmariesen Bristol-Myers Squibb 🚨